Furthermore, blocking S1P1 inhibits the amplification of inflammatory cytokines and the recruitment of immune cells in animal models, emphasizing the goal of MS treatment to hinder immune cell infiltration into the CNS. This evidence concerns the gene S1PR1 and myeloid sarcoma.